Nelconil (Nitrendipine)

Nelconil, a dihydropyridine calcium channel blocker, is employed in the management of elevated arterial pressure.

• Hypertension: reduces systolic and diastolic blood pressure by relaxing vascular smooth muscle and decreasing peripheral resistance.

• Nitrendipine selectively inhibits L‑type calcium channels on vascular smooth‑muscle cells, preventing calcium influx that is required for contraction. This vasodilatory effect lowers peripheral vascular resistance, leading to a reduction in systemic blood pressure without significant direct cardiac depression.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness or light‑headedness: related to blood pressure lowering.
• Tachycardia: compensatory increase in heart rate.
• Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Myocardial infarction: rare but possible in patients with coronary artery disease.
• Hepatic dysfunction: abnormal liver enzymes or hepatitis.
• Allergic reaction: rash, pruritus, or anaphylaxis.
• Angio‑edema: swelling of face, lips, or throat.
• Arrhythmias: irregular heart rhythms in susceptible individuals.

Patients should be evaluated for factors that may influence safety and efficacy.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Hepatic impairment: use with caution, dose may need adjustment.
• Elderly patients: start at lower dose and monitor for dizziness.
• Concomitant antihypertensives: assess for additive blood‑pressure‑lowering effects.
• CYP3A4 inhibitors: avoid strong inhibitors that can raise drug levels.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nitrendipine may interact with other medicines, altering its effect or safety profile. Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma concentrations.

• Other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.
• Grapefruit juice: can markedly raise drug levels.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance antihypertensive effect, watch electrolytes.
• Beta‑blockers: additive blood‑pressure reduction.
• NSAIDs: may blunt antihypertensive response.
• Alcohol: can increase dizziness and hypotension.
• Calcium supplements: may reduce absorption if taken simultaneously.